HI-STIM: High-intensity Strength Training in Myositis
Study Details
Study Description
Brief Summary
This study evaluates the effects of a high-intensity strength training in patients with myositis with the primary outcome being quality of life (SF-36). The study is designed as a parallel group randomised controlled trial with an intervention group and a control group.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Overall aim:
To investigate the effect of high-intensity strength training on quality of life, muscle strength, physical function, and disease activity in patients with myositis
Study design:
60 myositis patients will be included in a 16-week high-intensity strength training study. Patients will be randomly allocated into 2 groups (strength training and control) in a 1:1 ratio.
User involvement:
Myositis patients has been recruited to a patient advisory board. The advisory board's objective is to give patient-oriented project feedback, thus improving the overall research project.
Intervention:
Two training session per week for 16 weeks. Sessions consists of 3 sets of each exercise corresponding to 10 RM. Training progression will be accounted for and training loads will be evaluated weekly. The training protocol will be a full-body protocol, i.e. all major muscle groups will be engaged during each training session.
Outcomes:
The primary outcome is the Physical Component Summary Measure from the quality of life questionnaire (SF-36). Secondary outcomes include strength measures, functional tests, disease activity measures, questionnaires (e.g. International physical activity questionnaire), DEXA whole body scans, blood samples and muscle biopsies.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: High-intensity strength training 16 weeks of high-intensity strength training two times per week. Participants will receive the usual care in accordance to myositis (various DMARDs, different from patient to patient) Interventions: Other: high-intensity strength training Drug: Usual care |
Other: High-intensity strength training
The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
Other Names:
|
| No Intervention: Control Participants receive the usual care in accordance to myositis (various DMARDs, different from patient to patient). Intervention: Drug: Usual care |
Outcome Measures
Primary Outcome Measures
- Quality of life (health survey (SF-36) subscale: Physical Component Summary) [16 weeks]
Quality of life will be evaluated with the short form (36) health survey (SF-36) subscale: Physical Component Summary. The scale ranges from 0 to 100 where 100 is the highest score.
Secondary Outcome Measures
- Leg power [16 weeks]
Power rig
- Handgrip strength [16 weeks]
Measured by a handheld dynamometer
- Functional Index 3 [16 weeks]
A test of muscle strength in a series of muscles, carried out by the physician or physiotherapist
- 30 seconds chair rise [16 weeks]
Participants are instructed to stand up and sit down on a chair as many times as possible in 30 sec.
- Timed up-and-go [16 weeks]
Participants are instructed to rise from a chair walk 3 m forward, pass a marking and return to the chair and sit down as fast as possible
- 2-minute walk test [16 weeks]
A 2-min maximal walk test where the participant is encouraged to cover the greatest distance possible.
- Balance [16 weeks]
Short physical performance battery - balance part
- Whole-body, appendicular and lower-limb lean mass [16 weeks]
Measured by Dual-energy X-ray absorptiometry
- Fat-free mass, body fat and total mass [16 weeks]
Measured by bioimpedance
- Physician Global Activity [16 weeks]
Physician's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease activity
- Patient Global Activity [16 weeks]
Patient's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease activity.
- Extra-muscular Disease Activity [16 weeks]
An assessment tool used by the physician to evaluate disease activity in various organ systems via a scoring system and a 0-10 cm scale, where the higher score indicates higher disease activity.
- Manual muscle test 8 [16 weeks]
A test of muscle strength in a series of muscles, carried out by the physician
- Health Assessment Questionnaire (HAQ) [16 weeks]
HAQ is a questionnaire to evaluate patient reported disability. It has 8 categories with a range of questions. Each question is scored from 0 to 3 where 0 is no disability and 3 is unable to do.
- Physician Global assessment of disease damage [16 weeks]
Physician's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease damage.
- Patient Global assessment of disease damage [16 weeks]
Patient's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease damage.
- Medical history [16 weeks]
Questionnaire: Basic cardiovascular questionnaire concerning medical conditions, current medication, heart symptoms and smoking habits
- Self-perceived physical activity levels [16 weeks]
International Physical Activity Questionnaire - long
- Quality of life (health survey (SF-36) subscale: Mental component summary) [16 weeks]
Quality of life will be evaluated with the short form (36) health survey (SF-36) subscale: Mental Component Summary. The scale ranges from 0 to 100 where 100 is the highest score.
- Body mass index (BMI) [16 weeks]
Weight will be measured by scale (kg). Height will be measured by measuring (m). BMI will be derived from weight and height (kg/m^2)
- Systolic and diastolic blood pressure [16 weeks]
Measured by blood pressure monitor
- Blood samples (analysis of markers of af disease activity) [16 weeks]
Plasma analysis: lipid profile, HbA1c, troponins, NT-proBNP, creatine kinase
- Electrocardiography (ECG) [16 weeks]
Standard 12-lead ECG at 25 mm/s is recorded and analyzed according to standard published criteria (48-50). According to the Minnesota coding the PQ-interval is measured and presence of 1st, 2nd (including Mobitz type 1 and 2), and 3rd degree of AV block are noted. Additional measures will include: P-wave duration (≥ 2.5 mm in any of leads II, III, aVF), QRS duration (≥ 120 ms in any of leads I, II, III, aVL, aVF), QTc duration (> 450 ms), atrial fibrillation and flutter.
Other Outcome Measures
- Muscle biopsies [16 weeks]
Muscle biopsies will be taken on a selected number of subjects from either the vastus lateralis or the tibialis anterior muscle, for the use in future analysis of i.e. muscle fibre size and distribution, myogenic stem cell activity, capillary density, muscle inflammation ect.
- Physical activity level [16 weeks]
Will be measured by activity tracker (watch)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Fulfilling the criteria for myositis by EULAR/ACR (Bottai et al., 2017; Lundberg et al., 2017)
-
≤ 5 mg/day Prednisolone
-
Stable dosage of immunosuppressive treatment for at least 1 months prior to inclusion in the study
-
Myositis diagnosis at least 6 months prior to inclusion in the study
Exclusion Criteria:
-
Patients with sporadic inclusion body myositis and overlap myositis (myositis combined with another autoimmune rheumatic diseases, except Sjögren's Syndrome)
-
Co-morbidity preventing resistance training (severe heart/lung-disease, uncontrolled hypertension (systolic > 160mmHg, diastolic > 100mmHg), severe knee/hip arthritis)
-
Alcohol- and/or drug abuse. Defined by the guidelines issued by The Danish Health Authority
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rigshospitalet | Copenhagen | Denmark | 2100 |
Sponsors and Collaborators
- Rigshospitalet, Denmark
- University of Southern Denmark
- Odense University Hospital
Investigators
- Principal Investigator: Louise Pyndt Diederichsen, PhD, Rigshospitalet, Denmark
Study Documents (Full-Text)
None provided.More Information
Publications
- Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland) . EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017.
- Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. Epub 2017 Oct 27. Erratum in: Arthritis Rheumatol. 2018 Sep;70(9):1532.
- MCT16072020